Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Y-mAbs Therapeutics, Inc. YMAB
$9.08
-$0.12 (-1.30%)
На 18:01, 12 мая 2023
+191.85%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
402268854.00000000
-
week52high
20.48
-
week52low
2.70
-
Revenue
65267000
-
P/E TTM
-3
-
Beta
0.76684700
-
EPS
-2.26000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 20:00
Описание компании
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| BMO Capital | Outperform | 24 июн 2022 г. | |
| HC Wainwright & Co. | Buy | Buy | 28 февр 2022 г. |
| JP Morgan | Neutral | Neutral | 03 янв 2022 г. |
| JP Morgan | Neutral | Overweight | 16 ноя 2021 г. |
| HC Wainwright & Co. | Buy | Buy | 28 июн 2021 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 09 сент 2022 г. |
| BMO Capital | Outperform | Outperform | 01 ноя 2022 г. |
| Wedbush | Neutral | Outperform | 31 окт 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 31 окт 2022 г. |
| Canaccord Genuity | Buy | Buy | 31 окт 2022 г. |
| Cowen & Co. | Market Perform | Outperform | 05 янв 2023 г. |
| B of A Securities | Neutral | Buy | 02 дек 2022 г. |
| BMO Capital | Outperform | Outperform | 30 янв 2023 г. |
| Morgan Stanley | Underweight | Equal-Weight | 27 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Wilms Joris | A | 32000 | 32000 | 26 янв 2023 г. |
| Smith Susan Laura | A | 32000 | 32000 | 26 янв 2023 г. |
| Rajah Vignesh | A | 32000 | 32000 | 26 янв 2023 г. |
| Lund-Hansen Torben | A | 32000 | 32000 | 26 янв 2023 г. |
| Lisby Steen | A | 32000 | 32000 | 26 янв 2023 г. |
| Lund-Hansen Torben | A | 35700 | 35700 | 17 янв 2023 г. |
| Lund-Hansen Torben | A | 17800 | 17800 | 17 янв 2023 г. |
| Rajah Vignesh | A | 35700 | 35700 | 17 янв 2023 г. |
| Rajah Vignesh | A | 17800 | 17800 | 17 янв 2023 г. |
| Lisby Steen | A | 35700 | 35700 | 17 янв 2023 г. |
Новостная лента
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
08 мая 2023 г. в 19:03
Y-mAbs Therapeutics, Inc. (YMAB) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.64 per share a year ago.
Y-mAbs to Announce First Quarter 2023 Financial and Operating Results on May 8, 2023
GlobeNewsWire
28 апр 2023 г. в 09:00
NEW YORK, April 28, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter ended March 31, 2023, on Monday, May 8, 2023, after the close of the U.S. financial markets. The announcement will be followed by a conference call and webcast with the investment community on Tuesday, May 9, 2023, at 9:00 a.m. ET. Participating on the call from Y-mAbs will be Thomas Gad, founder, Chairman and Interim CEO; Bo Kruse, Chief Financial Officer; Sue Smith, Chief Commerical Officer and Vignesh Rajah, Chief Medical Officer.
Wall Street Analysts Believe Y-mAbs Therapeutics, Inc. (YMAB) Could Rally 111.13%: Here's is How to Trade
Zacks Investment Research
05 апр 2023 г. в 11:26
The consensus price target hints at an 111.1% upside potential for Y-mAbs Therapeutics, Inc. (YMAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Y-mAbs Therapeutics, Inc. (YMAB) Surges 13.8%: Is This an Indication of Further Gains?
Zacks Investment Research
04 апр 2023 г. в 06:52
Y-mAbs Therapeutics, Inc. (YMAB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Y-mAbs Therapeutics, Inc. (YMAB) Surpasses Q4 Earnings and Revenue Estimates
Zacks Investment Research
30 мар 2023 г. в 19:12
Y-mAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of 106.82% and 50.80%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?